Ginkgo Bioworks Holdings, Inc.

NYSE:DNA

Biotechnology

Healthcare
$8.44 +3.04%

+$0.26 today

Market cap
$547.12M
Beta
1.80
P/E (TTM)
-1.7
EPS (TTM)
-$5.11
52W Low $5.37High $17.58

Volume 2.36M

Average 1.24M

DNA Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Ginkgo Bioworks Holdings, Inc.NYSE: DNA

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $15.85M fell 22.4% year over year, behind the -1.5% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 24.6% from the prior quarter. Over 3 fiscal years it compounded at -65.2% a year.

Context

  • Stock-based compensation amounted to 47.9% of revenue in FY2025, down 1.6 pp from a year earlier.
  • Stock-based compensation increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -22.4% toward the trailing-twelve-month pace of -1.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$15.85M-24.6% QoQ
Last fiscal yearDec 2025
$81.55M-27.4% YoY
LTMMar 2026
$76.97M-1.5% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-22.4%——
1 year-27.4%——
3-year CAGR-65.2%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
81.55M USD
Year-over-year change
-27.4%
4-year CAGR
-52.5%

Stock-Based Compensation vs competitors

How DNA compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -1.5% is the 5th highest of 9, against a peer median of +5.3%.
  • Stock-based compensation amounts to 54.5% of revenue for DNA, versus a peer median of 16.7%.
DNA Competitors
Stock-Based Compensation for DNA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DNAGinkgo Bioworks Holdings, Inc.LTM Mar 2026$76.97M USD-1.5%-65.2%54.5%
MGTXMeiraGTx Holdings plcLTM Mar 2026$47.93M USD+107.3%-8.3%60.1%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$46.65M USD-42.2%-9.8%12.3%
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$41.75M USD+456.0%+204.9%—
VIRVir Biotechnology, Inc.LTM Mar 2026$35.01M USD+17.1%-21.7%53.5%
REPLReplimune Group, Inc.LTM Dec 2025$32.43M USD-6.5%+13.1%—
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026$26M USD-36.2%—12.5%
ARVNArvinas, Inc.LTM Mar 2026$18.8M USD-77.8%-16.5%21.0%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$15.73M USD+224.1%+209.1%—
VALNValneva SELTM Mar 2026€0 EUR——0.0%
Peer median (excluding DNA) —+5.3%-8.3%16.7%

Competitors are the stored peer set for DNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(1.84B)(2.11B)(892.87M)(547.03M)(312.76M)
Depreciation & Amortization29.08M42.55M71.55M63.02M58.99M
Deferred Income Tax30.21M(14.61M)(801K)(936K)(1.36M)
Stock-Based Compensation1.61B1.93B229.88M112.34M81.55M
Change in Working Capital(61.54M)(37.01M)29.84M(89.67M)(44.09M)
Accounts Receivables(114.09M)55.02M50.07M(4.73M)(1.47M)
Inventory(626K)164K000
Accounts Payables(2.25M)(10.84M)(1.18M)4.77M(2.99M)
Other Working Capital55.43M(81.35M)(19.05M)(89.72M)(39.62M)
Other Non-Cash Items(20.95M)(67.4M)266.9M142.69M46.62M
Operating Cash Flow(253.82M)(252.2M)(295.5M)(319.59M)(171.06M)
Capital Expenditures(56.52M)(52.27M)(40.8M)(62.54M)(7.67M)
Acquisitions (Net)(12.04M)26.65M(38.55M)(5.4M)0
Purchases of Investments(5M)(3.69M)00(418.63M)
Sales of Investments0004.52M185.38M
Other Investing Activities304K(38.08M)(1.34M)1.19M624K
Investing Cash Flow(73.26M)(67.39M)(80.69M)(62.24M)(240.29M)
Debt Repayment(1.12M)(1.24M)(1.3M)(897K)(354K)
Common Stock Issued099.3M080K19.47M
Common Stock Repurchased(25M)0(23K)00
Dividends Paid00000
Other Financing Activities1.56B(2.73M)(1.43M)(922K)(1.34M)
Financing Cash Flow1.53B95.34M(3.22M)(1.74M)17.78M
Effect of Forex Changes(19K)908K(588K)(281K)395K
Net Change in Cash1.21B(223.35M)(380M)(383.84M)(393.18M)
Free Cash Flow(310.34M)(304.47M)(336.3M)(382.13M)(178.72M)

Ginkgo Bioworks Holdings, Inc.

NYSE:DNA

Intrinsic Alpha fair value

Locked

Current Price

$8.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.